{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:27:12Z","timestamp":1786987632688,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug survival of older biologic therapies is thought to be influenced by the availability of newer biologic therapies and lower-cost biosimilars. However, there are limited data examining changes in drug survival over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine the drug survival of adalimumab over the past two decades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational, retrospective, multicentre cohort study analysed data from patients with moderate-to-severe psoriasis treated with adalimumab registered in the Danish nationwide registry, DERMBIO. Patients were stratified into two distinct time periods based on initiation date: an early period (2007\u20132016) and a late period (2019\u20132024). Kaplan\u2013Meier curves were used to present unadjusted drug survival curves. A multivariable adjusted Cox proportional hazards model was used to compare the risk of drug discontinuation between the two periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 2336 patients were included: 861 in the early period and 1475 in the late period. We found a significantly lower risk of drug discontinuation in the late period compared with the early period (adjusted hazard ratio 0.78, 95% confidence interval 0.68\u20130.90, P &amp;lt; 0.001), despite the concurrent availability of newer and more effective biologic therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study found that the increased number of available biologic therapies did not have a negative impact on the drug survival of adalimumab. On the contrary, discontinuation risk was significantly lower in 2019\u20132024 compared with 2007\u20132016. The concurrent introduction of lower-cost biosimilars and the associated rise in dose escalation may have contributed to the improved drug survival observed in the later period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag142","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:38:30Z","timestamp":1774355910000},"page":"1621-1628","source":"Crossref","is-referenced-by-count":0,"title":["Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2400-3971","authenticated-orcid":false,"given":"Gustav","family":"Hjort","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital , Herlev and Gentofte, Copenhagen ,","place":["Denmark"]},{"name":"Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital , Herlev and Gentofte, Copenhagen ,","place":["Denmark"]},{"name":"Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Bryld","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital , Roskilde ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawa K","family":"Ajgeiy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads K","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Bertelsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper F","family":"Hjuler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aalborg University Hospital , Aalborg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas N","family":"Dam","sequence":"additional","affiliation":[{"name":"Dermatology Clinic , Nykoebing Falster ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital , Herlev and Gentofte, Copenhagen ,","place":["Denmark"]},{"name":"Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital , Herlev and Gentofte, Copenhagen ,","place":["Denmark"]},{"name":"Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2026081712362591600_llag142-B1","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026081712362591600_llag142-B2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jdv.12817","article-title":"PASI90 response: the new standard in therapeutic efficacy for psoriasis","volume":"29","author":"Puig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081712362591600_llag142-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2015.171","article-title":"Drug survival studies in dermatology: principles, purposes, and pitfalls","volume":"135","author":"van den Reek","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2026081712362591600_llag142-B4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/bjd.19701","article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis","volume":"184","author":"Graier","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026081712362591600_llag142-B5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026081712362591600_llag142-B6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026081712362591600_llag142-B7","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jamainternmed.2020.0338","article-title":"Shift from adalimumab originator to biosimilars in Denmark","volume":"180","author":"Jensen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026081712362591600_llag142-B8","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jid.2023.04.009","article-title":"Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3\u2005years of treatment \u2013 a nationwide cohort study","volume":"143","author":"Thein","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2026081712362591600_llag142-B9","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040296","article-title":"Strengthening the reporting of observational studies in epidemiology (StroBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLOS Med"},{"key":"2026081712362591600_llag142-B10","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/jdv.16205","article-title":"Drug survival in patients with psoriasis is associated with the availability of biologic medications","volume":"34","author":"Shalom","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081712362591600_llag142-B11","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/ced.15288","article-title":"Real-world dose adjustments of biologic treatments in psoriasis and their economic impact: a Swedish national population study","volume":"47","author":"Egeberg","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2026081712362591600_llag142-B12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1684\/ejd.2020.3751","article-title":"Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients","volume":"30","author":"Bardazzi","year":"2020","journal-title":"Eur J Dermatol"},{"key":"2026081712362591600_llag142-B13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/jdv.14926","article-title":"Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis","volume":"32","author":"Gniadecki","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081712362591600_llag142-B14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1365-2133.2012.11041.x","article-title":"Efficacy, safety and medication cost implications of adalimumab 40\u2005mg weekly dosing in patients with psoriasis with suboptimal response to 40\u2005mg every other week dosing: results from an open-label study","volume":"167","author":"Leonardi","year":"2012","journal-title":"Br J Dermatol"},{"key":"2026081712362591600_llag142-B15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jid.2018.08.012","article-title":"Adalimumab in psoriasis: how much is enough?","volume":"139","author":"Billi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2026081712362591600_llag142-B16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2026081712362591600_llag142-B17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/ijd.17704","article-title":"Early use of beneficial biological therapy on younger psoriasis patients: could a \u2018step-down\u2019 therapy approach be more effective?","volume":"64","author":"Behlock","year":"2025","journal-title":"Int J Dermatol"},{"key":"2026081712362591600_llag142-B18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jvc2.63","article-title":"Early intervention and disease memory in psoriasis: a literature review","volume":"1","author":"Ben Abdallah","year":"2022","journal-title":"JEADV Clin Pract"},{"key":"2026081712362591600_llag142-B19","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/ced\/llaf224","article-title":"Evaluating changes in baseline characteristics and drug utilisation pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immuno\u00admodulators Register (BADBIR) Cohort","volume":"50","author":"Alabas","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026081712362591600_llag142-B20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026081712362591600_llag142-B21","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2026081712362591600_llag142-B22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.17738","article-title":"Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis","volume":"181","author":"Mourad","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag142\/67507183\/llag142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/9\/1621\/67507183\/llag142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/9\/1621\/67507183\/llag142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:36:38Z","timestamp":1786984598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/9\/1621\/8540111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,25]]},"published-print":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag142","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,25]]}}}